[FONT="][FONT=Arial]Is anyone in a position to apply for grants? This could be a great opportunity for funding for e-cig research.(even if it does fall into medication rather than tobacco alternative category) [/FONT]
[/FONT][/COLOR][B][COLOR=black][FONT="]_____________
Medication Initiative for tobacco Dependence (MITD): A New Product Development Partnership [/FONT][/B]
(PDP)(UH2/UH3) RFA-DA-11-015: Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)
RFA-DA-11-015
Letter of Intent Due Date: March 26, 2011
Application Due Date: April 26, 2011 by 5:00PM local time of applicant organization
FOA Purpose:
The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from qualified non-profit, private and academic researchers/organizations to participate in the planning and execution of a new public-private partnership (PPP). The purpose of a one-year planning phase (UH2) is to provide support for the systematic study directed toward fuller scientific understanding of the opportunities in the area of drug discovery and development for tobacco dependence, with the ultimate goal of establishing a PPP, specifically, a Product Development Partnership (PDP). The mission of the PDP is to develop safe and effective medications for the treatment of tobacco dependence, including aids for smoking cessation. Phase two (UH3) funding will be utilized to support the implementation and execution phase of the PDP, with one selected cooperative agreement recipient assuming the role of the PDP’s Managing Partner. In this subsequent phase, the PDP will conduct a wide array of research and development (R&D) projects aimed at the fulfillment of regulatory requirements for approval for marketing in the US.
See announcement for complete information RFA-DA-11-015: Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)
Please send inquiries to Medications Initiative for Tobacco Dependence: NIDAMedTDWG@mail.nih.gov or call 301-443-9800
[/FONT][/COLOR][B][COLOR=black][FONT="]_____________
Medication Initiative for tobacco Dependence (MITD): A New Product Development Partnership [/FONT][/B]
(PDP)(UH2/UH3) RFA-DA-11-015: Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)
RFA-DA-11-015
Letter of Intent Due Date: March 26, 2011
Application Due Date: April 26, 2011 by 5:00PM local time of applicant organization
FOA Purpose:
The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from qualified non-profit, private and academic researchers/organizations to participate in the planning and execution of a new public-private partnership (PPP). The purpose of a one-year planning phase (UH2) is to provide support for the systematic study directed toward fuller scientific understanding of the opportunities in the area of drug discovery and development for tobacco dependence, with the ultimate goal of establishing a PPP, specifically, a Product Development Partnership (PDP). The mission of the PDP is to develop safe and effective medications for the treatment of tobacco dependence, including aids for smoking cessation. Phase two (UH3) funding will be utilized to support the implementation and execution phase of the PDP, with one selected cooperative agreement recipient assuming the role of the PDP’s Managing Partner. In this subsequent phase, the PDP will conduct a wide array of research and development (R&D) projects aimed at the fulfillment of regulatory requirements for approval for marketing in the US.
See announcement for complete information RFA-DA-11-015: Medication Initiative for Tobacco Dependence (MITD): A New Product Development Partnership (PDP)(UH2/UH3)
Please send inquiries to Medications Initiative for Tobacco Dependence: NIDAMedTDWG@mail.nih.gov or call 301-443-9800
